Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 912

1.

Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors.

Tuna M, Amos CI, Mills GB.

Oncotarget. 2019 Mar 12;10(21):2095-2111. doi: 10.18632/oncotarget.26777. eCollection 2019 Mar 12. Review.

2.

Integrated transcriptomic-genomic tool Texomer profiles cancer tissues.

Wang F, Zhang S, Kim TB, Lin YY, Iqbal R, Wang Z, Mohanty V, Sircar K, Karam JA, Wendl MC, Meric-Bernstam F, Weinstein JN, Ding L, Mills GB, Chen K.

Nat Methods. 2019 Apr 15. doi: 10.1038/s41592-019-0388-9. [Epub ahead of print]

PMID:
30988467
3.

Breast cancer quantitative proteome and proteogenomic landscape.

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF, Schlichting E, Naume B; Consortia Oslo Breast Cancer Research Consortium (OSBREAC), Luders T, Borgen E, Kristensen VN, Russnes HG, Lingjærde OC, Mills GB, Sahlberg KK, Børresen-Dale AL, Lehtiö J.

Nat Commun. 2019 Apr 8;10(1):1600. doi: 10.1038/s41467-019-09018-y.

4.

Prospective Clinical Sequencing of Adult Glioma.

Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF.

Mol Cancer Ther. 2019 Mar 29. doi: 10.1158/1535-7163.MCT-18-1122. [Epub ahead of print]

PMID:
30926639
5.

GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.

Maric G, Annis MG, MacDonald PA, Russo C, Perkins D, Siwak DR, Mills GB, Siegel PM.

Oncogene. 2019 Mar 26. doi: 10.1038/s41388-019-0793-7. [Epub ahead of print]

PMID:
30914799
6.

Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity.

Rozanov D, Cheltsov A, Nilsen A, Boniface C, Forquer I, Korkola J, Gray J, Tyner J, Tognon CE, Mills GB, Spellman P.

PLoS One. 2019 Mar 25;14(3):e0205623. doi: 10.1371/journal.pone.0205623. eCollection 2019.

7.

Protein Kinase C Quality Control by Phosphatase PHLPP1 Unveils Loss-of-Function Mechanism in Cancer.

Baffi TR, Van AN, Zhao W, Mills GB, Newton AC.

Mol Cell. 2019 Apr 18;74(2):378-392.e5. doi: 10.1016/j.molcel.2019.02.018. Epub 2019 Mar 20.

PMID:
30904392
8.

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, Blocker AW, Eattock N, Gnerre S, Satya RV, Xu H, Zhao C, Hall MP, Hu Y, Sehnert AJ, Brown D, Ladanyi M, Rudin CM, Hunkapiller N, Feeney N, Mills GB, Paweletz CP, Janne PA, Solit DB, Riely GJ, Aravanis A, Oxnard GR.

Ann Oncol. 2019 Mar 20. pii: mdz046. doi: 10.1093/annonc/mdz046. [Epub ahead of print]

PMID:
30891595
9.

Therapeutic Clues from an Integrated Omic Assessment of East Asian Triple Negative Breast Cancers.

Heiser LM, Mills GB, Gray JW.

Cancer Cell. 2019 Mar 18;35(3):341-343. doi: 10.1016/j.ccell.2019.02.012.

PMID:
30889376
10.

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.

Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

PMID:
30880072
11.

Critical Questions in Ovarian Cancer Research and Treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.

Cancer. 2019 Mar 5. doi: 10.1002/cncr.32004. [Epub ahead of print]

PMID:
30835824
12.

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.

Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J.

Sci Rep. 2019 Feb 12;9(1):1853. doi: 10.1038/s41598-019-38534-6.

13.

Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer.

Li X, Mak VCY, Zhou Y, Wang C, Wong ESY, Sharma R, Lu Y, Cheung ANY, Mills GB, Cheung LWT.

Nat Commun. 2019 Feb 12;10(1):716. doi: 10.1038/s41467-019-08574-7.

14.

Correction: Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.

Kang MH, Jeong KJ, Kim WY, Lee HJ, Gong G, Suh N, Győrffy B, Kim S, Jeong SY, Mills GB, Park YY.

Oncogene. 2019 Feb 4. doi: 10.1038/s41388-019-0721-x. [Epub ahead of print]

PMID:
30718918
15.

Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.

Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR.

J Exp Med. 2019 Feb 4;216(2):419-427. doi: 10.1084/jem.20181936. Epub 2019 Jan 25.

PMID:
30683736
16.

Correction: RCP induces Slug expression and cancer cell invasion by stabilizing β1 integrin.

Hwang MH, Cho KH, Jeong KJ, Park YY, Kim JM, Yu SL, Park CG, Mills GB, Lee HY.

Oncogene. 2019 Jan 24. doi: 10.1038/s41388-019-0678-9. [Epub ahead of print]

PMID:
30679788
17.

Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.

Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Leverson JD, Sampath D, Mills GB, Brugge JS.

Mol Cancer Ther. 2019 Mar;18(3):642-655. doi: 10.1158/1535-7163.MCT-18-0413. Epub 2019 Jan 24.

PMID:
30679390
18.
19.

Implementing a comprehensive translational oncology platform: from molecular testing to actionability.

Mitri ZI, Parmar S, Johnson B, Kolodzie A, Keck JM, Morris M, Guimaraes AR, Beckett BR, Borate U, Lopez CD, Kemmer KA, Alumkal JJ, Beer TM, Corless CL, Mills GB, Gray JW, Bergan RC.

J Transl Med. 2018 Dec 14;16(1):358. doi: 10.1186/s12967-018-1733-y.

20.

Significant Excess of Electronlike Events in the MiniBooNE Short-Baseline Neutrino Experiment.

Aguilar-Arevalo AA, Brown BC, Bugel L, Cheng G, Conrad JM, Cooper RL, Dharmapalan R, Diaz A, Djurcic Z, Finley DA, Ford R, Garcia FG, Garvey GT, Grange J, Huang EC, Huelsnitz W, Ignarra C, Johnson RA, Karagiorgi G, Katori T, Kobilarcik T, Louis WC, Mariani C, Marsh W, Mills GB, Mirabal J, Monroe J, Moore CD, Mousseau J, Nienaber P, Nowak J, Osmanov B, Pavlovic Z, Perevalov D, Ray H, Roe BP, Russell AD, Shaevitz MH, Spitz J, Stancu I, Tayloe R, Thornton RT, Tzanov M, Van de Water RG, White DH, Wickremasinghe DA, Zimmerman ED; MiniBooNE Collaboration.

Phys Rev Lett. 2018 Nov 30;121(22):221801. doi: 10.1103/PhysRevLett.121.221801.

PMID:
30547637

Supplemental Content

Loading ...
Support Center